Techmotion Technology Spółka z Ograniczoną Odpowiedzialnością (KRS 0000615481, NIP 7972057356) is a Polish company, headquartered in Warszawa, Mazowieckie voivodeship. TECHMOTION TECHNOLOGY operates in: Other research and experimental development on natural sciences and engineering (PKD 72.19.Z). Industry: Research and development. The company has been listed in the National Court Register since April 28, 2016.
Historical suspension of activities
Suspension: December 31, 2023 - resumed: January 1, 2026
Negative equity
Negative equity in 3 of 4 available reporting years.
No arrears identified in the analyzed sources
No arrears or bankruptcy proceedings identified in the analyzed sources.
Business profile - Techmotion Technology
Identity
- Name
- Techmotion Technology Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
- Founded
- April 28, 2016
- Registry status as of
- May 22, 2026
- Latest entry
- May 22, 2026
- Founding act
- 25.04.2016 R.,
Articles of association history (2)
- April 25, 2016: 25.04.2016 R.,
- December 9, 2016: AKT NOTARIALNY Z DNIA 09.12.2016R. REP. A 10511/2016, NOTARIUSZ TADEUSZ MIRON HAMERA KANCELARIA NOTARIALNA 05-600 GRÓJEC UL.SPORTOWA 4A, ZMIANA PAR.3 I PAR.4 PO PUNKCIE 28 DODAJE SIĘ KOLEJNY PUNKT 29, ZMIANA PAR.5
Activities
Main activity
72.19.ZOther research and experimental development on natural sciences and engineering
Other activities
General codes (divisions and groups)
General codes indicate a PKD division or group without a specific subclass.
Address and contact
- Address
- UL. NOWOLIPIE, 7A, LU5, 00-146, WARSZAWA, POLSKA
- Voivodeship
- MAZOWIECKIE
- District
- WARSZAWA
- WPARADOWSKA@PARDEX.PL
- Website
- Not disclosed in the registry
- E-delivery address
- Not disclosed in the registry
Risk and payment profile - Techmotion Technology
Credibility rating
27.8 / 100
Poor credibility
Insolvency risk
Moderate
Significant formal threat
Closure risk
32
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organizational stability signals
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
1
1/10 yrs
Board changes
0
0/10 yrs
PKD changes
1
1/10 yrs
Name changes
0
0/10 yrs
Data from 10 years of registry activity.
Credibility history
Payment reliability score from 2018–2025
Current: E (28/100)
Trend: improving (+5.8 pts/year)
Bardzo słaba wiarygodność płatnicza – współpraca handlowa wiąże się z wysokim ryzykiem braku zapłaty.
Trade credit limit history
Standard limit from 2018–2025
Current: 0 PLN
Safe: 0 PLN
Operational status - Techmotion Technology
Founded
April 28, 2016
10 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
WARSZAWA
MAZOWIECKIE
Primary PKD
72.19.Z
Other research and experimental development on natural sciences and…
Share capital
200.0 K PLN
2,000 shares total
Shareholders
1
shareholder
Board
1 person
Filed years
4 years
2018–2025 · profitable: 0/4
Registry entries
30
latest: May 22, 2026
Risk signals
Revenue
N/A
2025
Net profit
N/A
2025
Assets
1.7 M PLN
2025
Equity
-149.2 K PLN
2025
EBITDA
N/A
2025
no depreciation data
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - Techmotion Technology.
No ratings
Related articles
News
Bioceltix in the final EMA dialogue phase: BCX-CM-J could become Europe's first veterinary cell-therapy drug for dogs
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase regarding BCX-CM-J - Europe's first veterinary cell-therapy drug from mesenchymal stem cells for dogs with osteoarthritis. Responses to the final EMA questions are due in May 2026; the CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. Pre-commercial biotech: 2024 closed with a PLN 14.9 m loss on zero revenue; cash of PLN 33.6 m at year-end. Trigon DM maintained a buy rating with a price target of PLN 127.2.
News
Captor Therapeutics: PLN 36 m of cash at 30 September 2025, runway to mid-2026 - clinical data versus the cash clock
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) - a pre-commercial biotech specialising in TPD (Targeted Protein Degradation) - closed Q3 2025 with PLN 36 m of cash and grants securing financing to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I - the first patient dosed at Barcelona Clinic Liver Cancer. CT-03 (MCL-1 degrader) nearing clinical entry. Without a new R&D partnership or equity issuance in 2026, the company will need additional financing.
